QUAGLINO, Pietro
QUAGLINO, Pietro
SCIENZE MEDICHE
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors
2022-01-01 Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro
'Aleukemic' granulomatous leukemia cutis.
1998-01-01 TOMASINI C ;QUAGLINO P ;NOVELLI M ;FIERRO MT
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed?
2012-01-01 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
2017-01-01 Kim, Y.H.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W.L.; Lin, H.; Little, M.; Prince, H.
593 Inverse psoriasis involvement in moderate to severe psoriatic patients: A comparison between anti IL23 and anti IL17
2023-01-01 Mastorino, L.; Macagno, N.; Dapavo, P.; Ribero, S.; Quaglino, P.
A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site
2020-01-01 Ramondetta, Alice; Ribero, Simone; Conti, Luca; Quaglino, Pietro; Broganelli, Paolo
A literature revision in primary cutaneous B-cell lymphoma
2017-01-01 La Selva, R; Alberti Violetti, S.; Delfino, C.; Grandi, V.; Cicchelli, S.; Tomasini CF; Fierro, M.T.; Berti, E.; Pimpinelli, N.; Quaglino, P.
A meta-analysis of melanoma risk in industrial workers
2018-01-01 Vujic, Igor; Gandini, Sara; Stanganelli, Ignazio; Fierro, Maria T; Rappersberger, Klemens; Sibilia, Maria; Tosti, Giulio; Ferrucci, Pier F; Caini, Saverio; De Felici, Maria B; Pagliarello, Calogero; Quaglino, Pietro; Sanlorenzo, Martina
A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study
2019-01-01 Stadler, R.; Scarisbrick, J.; Knobler, R.; Quaglino, P.; Borgmann, M.; Orlovius, M.; Reimann, P.; Danhauser-Riedl, S.
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
2017-01-01 Bagot M, Hasan B, Whittaker S, Beylot-Barry M, Knobler R, Shah E., Marreaud S, Morris S, Dalle S, Servitje O, Cowan R, Väkevä L, Chaby G, Jonak C., Fox C.P., Ritchie D, Vermeer M.H., Stadler R., Romero P.L.O., Scarisbrick J., Quaglino, P.
A project by the SIDeMaST Immunopathology Group on cutaneous vasculitis
2015-01-01 Papini, M; Quaglino, P.; La Placa, M.; Marzano, A.V.
A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii)
2021-01-01 Atkinson V.G.; Quaglino P.; Aglietta M.; Del Vecchio M.; Depenni R.; Consoli F.; Bafaloukos D.; Ferrucci P.F.; Tulyte S.; Krajsova I.; Ascierto P.A.; Gueli R.; Arance A.; Gogas H.; Banerjee H.; Saliba T.; de Jong E.; Neyns B.
A simple scoring system for the diagnosis of palmo-plantar pigmented skin lesions by digital dermoscopy analysis.
2012-01-01 Rubegni P; Cevenini G; Nami N; Argenziano G; Saida T; Burroni M; Quaglino P; Bono R; Hofmann-Wellenhof R; Fimiani M.
A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides.
2014-01-01 Ferrara G; Pancione M; Votino C; Quaglino P; Tomasini C; Santucci M; Pimpinelli N; Cusano F; Sabatino L; Colantuoni V.
A traveller's wart: tungiasis
2018-01-01 Fava, Paolo; Astrua, Chiara; Brizio, Matteo; Cavaliere, Giovanni; Senetta, Rebecca; Fierro, Maria Teresa; Quaglino, Pietro
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies
2017-01-01 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Activity and safety of bexarotene as maienance therapy in CTCL patients with stable disease or remission after systemic treatments: a prospective multicenter trial from the GILC
2011-01-01 Quaglino P
Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC
2007-01-01 Pietro Quaglino; Maria Grazia Bernengo
Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC)
2011-01-01 Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors | 2022 | Mastorino, Luca; Susca, Sara; Cariti, Caterina; Verrone, Anna; Stroppiana, Elena; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone; Quaglino, Pietro | |
| 'Aleukemic' granulomatous leukemia cutis. | 1998 | TOMASINI C ;QUAGLINO P ;NOVELLI M ;FIERRO MT | |
| 1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed? | 2012 | Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo | |
| 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study | 2017 | Kim, Y.H.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W.L.; Lin, H.; Little, M.; Prince, H. | |
| 593 Inverse psoriasis involvement in moderate to severe psoriatic patients: A comparison between anti IL23 and anti IL17 | 2023 | Mastorino, L.; Macagno, N.; Dapavo, P.; Ribero, S.; Quaglino, P. | |
| A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site | 2020 | Ramondetta, Alice; Ribero, Simone; Conti, Luca; Quaglino, Pietro; Broganelli, Paolo | |
| A literature revision in primary cutaneous B-cell lymphoma | 2017 | La Selva, R; Alberti Violetti, S.; Delfino, C.; Grandi, V.; Cicchelli, S.; Tomasini CF; Fierro, M.T.; Berti, E.; Pimpinelli, N.; Quaglino, P. | |
| A meta-analysis of melanoma risk in industrial workers | 2018 | Vujic, Igor; Gandini, Sara; Stanganelli, Ignazio; Fierro, Maria T; Rappersberger, Klemens; Sibilia, Maria; Tosti, Giulio; Ferrucci, Pier F; Caini, Saverio; De Felici, Maria B; Pagliarello, Calogero; Quaglino, Pietro; Sanlorenzo, Martina | |
| A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study | 2019 | Stadler, R.; Scarisbrick, J.; Knobler, R.; Quaglino, P.; Borgmann, M.; Orlovius, M.; Reimann, P.; Danhauser-Riedl, S. | |
| A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. | 2011 | Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli | |
| A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. | 2017 | Bagot M, Hasan B, Whittaker S, Beylot-Barry M, Knobler R, Shah E., Marreaud S, Morris S, Dalle S, Servitje O, Cowan R, Väkevä L, Chaby G, Jonak C., Fox C.P., Ritchie D, Vermeer M.H., Stadler R., Romero P.L.O., Scarisbrick J., Quaglino, P. | |
| A project by the SIDeMaST Immunopathology Group on cutaneous vasculitis | 2015 | Papini, M; Quaglino, P.; La Placa, M.; Marzano, A.V. | |
| A retrospective analysis of dabrafenib and/or dabrafenib plus trametinib combination in patients with metastatic melanoma to characterize patients with long-term benefit in the individual patient program (Describe iii) | 2021 | Atkinson V.G.; Quaglino P.; Aglietta M.; Del Vecchio M.; Depenni R.; Consoli F.; Bafaloukos D.; Ferrucci P.F.; Tulyte S.; Krajsova I.; Ascierto P.A.; Gueli R.; Arance A.; Gogas H.; Banerjee H.; Saliba T.; de Jong E.; Neyns B. | |
| A simple scoring system for the diagnosis of palmo-plantar pigmented skin lesions by digital dermoscopy analysis. | 2012 | Rubegni P; Cevenini G; Nami N; Argenziano G; Saida T; Burroni M; Quaglino P; Bono R; Hofmann-Wellenhof R; Fimiani M. | |
| A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. | 2014 | Ferrara G; Pancione M; Votino C; Quaglino P; Tomasini C; Santucci M; Pimpinelli N; Cusano F; Sabatino L; Colantuoni V. | |
| A traveller's wart: tungiasis | 2018 | Fava, Paolo; Astrua, Chiara; Brizio, Matteo; Cavaliere, Giovanni; Senetta, Rebecca; Fierro, Maria Teresa; Quaglino, Pietro | |
| Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies | 2017 | Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario | |
| Activity and safety of bexarotene as maienance therapy in CTCL patients with stable disease or remission after systemic treatments: a prospective multicenter trial from the GILC | 2011 | Quaglino P | |
| Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC | 2007 | Pietro Quaglino; Maria Grazia Bernengo | |
| Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC) | 2011 | Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG |